Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554).
The aim of this work was to study the metabolic characteristics of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554). HPLC and 19F NMR methods were employed to evaluate the rate of reductive metabolism of SR-4554 and the nature of the resulting metabolites, respectively. SR-4554 was enzymatically reduced by mouse liver microsomes (1.1 +/- 0.1 nmol of SR-4554 reduced/min/mg protein), purified rat and human NADPH:cytochrome P450 reductase (17.8 +/- 0.4 and 5.0 +/- 0.5 nmol of SR-4554 reduced/min/mg protein, respectively), and SCCVII tumour homogenates (2.3 +/- 0.3 nmol of SR-4554 reduced/min/g tumour) under nitrogen. NADPH:cytochrome P450 reductase was a major microsomal enzyme involved in the bioreduction of SR-4554 by liver microsomes. In a panel of murine and human tumour xenografts, cytochrome P450 reductase activities were found to be low and only varied by 3-fold between different tumour types, suggesting that enzyme activities within the tumours are unlikely to influence markedly in vivo reductive metabolism. Reduction of SR-4554 by mouse liver microsomes showed a characteristic oxygen dependence with a half-maximal inhibition of 0.48 +/- 0.06%. Thus, the reductive metabolism of SR-4554 can be employed to detect the low oxygen tensions that occur within both murine and human tumours. Soluble, low molecular weight reductive metabolites of SR-4554 were identified by 19F NMR. These metabolite peaks appeared (up to 0.12 ppm) downfield of the parent drug peak. In conclusion, SR-4554 undergoes an oxygen-dependent metabolism that involves NADPH:cytochrome P450 reductase. 19F NMR is capable of identifying reduced metabolites that are undetectable by HPLC.